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Oncologia Sperimentale C, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
Summary The prognostic role of cell kinetics (expressed as 3H-thymidine labelling index, 3H-TdR LI) was
assessed on 145 patients with pathologic stage II melanoma subjected only to therapeutic lymph node
dissection. The 3H-TdR LI determined on metastatic nodes was related to relapse-free survival and to survival.
In particular, 3-year relapse-free survival was significantly different from patients with slowly and rapidly
proliferating melanomas (40% vs 22%, P=0.007), and this finding was consistently found for overall survival
(68% vs 46%, P=0.007). Moreover, in patients with high 3H-TdR LI tumours, the risk of relapse and death
within the first year from lymphadenectomy was two-fold that of patients with low 3H-TdR LI tumours.
Multiple regression analysis showed that 3H-TdR LI retained its prognostic significance on relapse-free and on
overall survival even when the number of involved nodes and type of nodal metastases were considered.
Present findings suggest that 3H-TdR LI can contribute to select high-risk stage II melanoma patients.
Prognosis in patients with stage II melanoma is related to
features of the primary tumour and of nodal metastases
(Balch et al., 1981; Cascinelli et al., 1984; Roses et al., 1985;
Koh et al., 1986; Kissin et al., 1987). Survival is inversely
related to the number of positive nodes and also decreases
when perilymph node invasion is present (Balch et al., 1981;
Rayner et al., 1981; Callery et al., 1982; Cascinelli et al.,
1984). However, it has also been emphasised that nodal
metastases are indicators, not determinants of survival in
pathologic stage II melanoma patients (Cady, 1984).
Cell kinetics, studied by different approaches, has emerged
as an important indicator of biologic aggressiveness (Bauer et
al., 1987; Kallioniemi et al., 1987; Quirke et al., 1987; Griffin
et al., 1988; Hall et al., 1988; Bouzubar et al., 1989). In
particular, the 3H-thymidine labelling index (3H-TdR LI) has
been shown to be a prognostic factor whose role remains also
in the presence of other clinico-pathologic prognostic factors
(Meyer et al., 1983; Silvestrini et al., 1986, 1989; Chauvel et
al., 1988).
Little attention has been given to cell kinetics in malignant
melanoma (Shirakawa et al., 1970; Hagemann & Schiffer,
1971; Newburger et al., 1980; Hansson et al., 1982; Costa et
al., 1987). The data available on preliminary series of stage II
melanoma patients strongly indicate the potential clinical
usefulness of cell kinetics as a prognostic marker (Hansson et
al., 1982; Costa et al., 1987). However, the relative contribu-
tion of cell kinetics in relation to information given by other
morphologic and pathologic features has been never
analysed.
In this follow-up study, we report on a group of 166
patients with pathologic stage II melanoma of the skin to
substantiate, in a larger series with a longer follow-up, our
preliminary findings. However, we investigated the possible
association of cell kinetics with established clinico-pathologic
parameters and we estimated the different contribution of all
the variables on the clinical course, in terms of relapse-free
interval and overall survival, by means of a multiple regres-
sion analysis.
The main basic limitation in starting the study was the
impossibility to perform the cell kinetics determination on
the primary tumour, which is completely reserved for the
pathologist for Clark's (1969) and Breslow's (1970) histologic
microstaging. This constraint was overcome by using the
metastatic nodal lesion. This decision is quite compatible
with the microscopic examination of autoradiograms, which
allows us accurately to score and consider only tumour cells.
Material and methods
Case series
The study was carried out on 166 patients with stage II
melanoma of the skin. Stage was assessed by conventional
clinical, radiological and radioisotopic examinations. All
patients underwent therapeutic radical lymph node dissection
at the Cancer Institute of Milan from November 1981 to
September 1987. The primary tumour had been previously
removed in 121 cases, and in 45 cases it was removed simul-
taneously with nodal dissection. No other treatment was
given until new disease manifestation was documented. Sixty-
six patients were females and 100 males. The median age at
the time of node dissection was 47 years (range 18-79 years).
A histopathological examination was performed to
evaluate the number and type of nodal metastases. Sixty-six
patients had one positive node (N + ), 41 patients had two,
12 patients had three and 47 patients had more than three
positive nodes. The group of patients defined by the type of
nodal involvement was numerically unbalanced. In fact, only
13 patients showed partial nodal invasion, 48 patients mas-
sive invasion still confined within the capsule, and 105
patients invasion beyond the capsule. This was due to the
impossibility to recognise by gross examination slightly or
partially involved metastases at the time of node dissection.
Cell kinetic determination
Cell kinetics was defined as in vitro 3H-TdR LI on fresh
pathologic lymph nodes immediately after dissection, as
previously described (Costa et al., 1987). Briefly, small
fragments were incubated with 3H-thymidine (6 jlCi ml1 ',
specific activity, 5 Ci mmol '; Radiochemical Centre, Amer-
sham, UK) in culture medium for 1 h at 37°C. Autoradio-
graphy was performed on histologic sections according to the
stripping film technique (Kodak AR10, Kodak, London,
UK), and the samples were stained with haematoxylin and
eosin. The 3H-TdR LI was determined by scoring at least
3,000 tumour cells per sample. The determination of 3H-TdR
LI on the sections from different samples of the same tumour
showed a median coefficient of variation of 25%.
Statistical methods
Comparison of the 3H-TdR LI values among the different
subsets identified by the various prognostic factors was done
by the Wilcoxon rank sum test. The Bonferroni procedure
was adopted to allow for multiple comparisons. The two
major end-points, relapse-free survival (RFS) and overall
survival, were computed from the time of node dissection
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until clinically evaluated relapse or death on 145 patients
with an adequate follow-up. The observation times ranged
from 1 to 75 months, and the median follow-up was 25
months. First of all, a univariate analysis was carried out to
estimate RFS and survival curves relative to the different
modalities of each prognostic variable by means of the Kap-
lan-Meier product-limit method (Kaplan & Meier, 1958).
Comparisons among curves were accomplished by resorting
to the log rank test (Mantel, 1966). The hazard function was
estimated according to the approach proposed by Simes and
Zelen (1985). Six-month intervals were chosen to calculate
the hazard estimates.
The joint effect of the variables, possibly influencing prog-
nosis, was investigated by a Cox's multiple regression model
(Cox, 1972).
The role of 3H-TdR LI was investigated after classifying
tumours in two classes with different proliferative rates. the
value of 8%, which represents the mean value of the distribu-
tion of this variable, was used to discriminate slowly and
rapidly proliferating melanomas. Other cut-off levels were
tested by means of the Kaplan-Meier product-limit method,
and the log rank test was used to assess differences in RFS
and survival between subgroups. x2 values with one degree of
freedom were calculated with the corresponding P values,
and the highest x2 value was observed at a 3H-TdR LI cut-off
of 8%.
Results
3H-TdR LI values defined for the overall series of 166 nodal
lesions were highly skewed, with a mean value of 8.6% and a
range from 0.3 to 31%, in agreement with our previous
results (Costa et al., 1987). Cell kinetics was analysed in
relation to the clinico-pathological features considered prog-
nostic factors in stage II melanoma patients (Table I). 3H-
TdR LI was not related to age or sex of the patient, to
number of positive nodes, or to type of metastases.
The overall 3-year RFS and survival for the series of 145
patients, for whom cell kinetic and follow-up information
was available, were 32% and 59%, respectively. This finding
is in agreement with other clinical reports on larger series of
stage II melanoma patients (Balch et al., 1981; Cascinelli et
al., 1984; Kissin et al., 1987). The analysis as a function of
3H-TdR LI showed significant differences in the probability
of RFS between patients with slowly and rapidly pro-
liferating tumours (40% vs 22%, P = 0.007) (Figure la). The
survival curves were also significantly different (68% vs 46%,
P = 0.007) (Figure lb). Relapse and death hazard over time
showed similar patterns for the two kinetics subsets of
patients (Figure 2), with a peak of risk from 6 to 12 months
from lymphadenectomy. The hazard was higher for patients
with rapidly proliferating tumours than for those with slowly
proliferating tumours for the whole follow-up period.
Univariate analysis of 3-year RFS and survival as a func-
tion of number of positive nodes and type of nodal invasion
was performed on the two subsets with less or more than two
positive nodes owing to the unbalanced number of cases
within the different categories. Patients with partial or mas-
sive nodal involvement were considered together. When
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Figure 1 Clinical outcome as a function of 3H-TdR LI of nodal
metastases in a series of 145 patients with stage II melanoma of
the skin. ---, low 3H-TdR LI; -, high 3H-TdR LI. a, relapse-
free survival; b, survival.
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Table I Relationship between cell kinetics and clinico-pathologic
features in stage II melanoma
No. of Labelling index (%)
cases Mean Range
Patient age (years)
< 40 55 8.5 0.9-31.1
<40 111 8.6 0.3-29.6
Sex
Males 100 8.3 0.3-29.6
Females 66 9.0 0.8-31.1
Nodal status
N + < 2 107 9.0 0.6-29.6
N+ >2 59 7.8 0.3-31.1
Type ofnodal metatasis
Intracapsular 61 7.6 0.8-24.8
Extracapsular 105 9.0 0.3-31.1
N
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Figure 2 Estimated hazard function of relapse and death (per
100 persons per 6 months) for patients with slowly (---) and
rapidly (-) proliferating tumours.
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singly tested, number of positive nodes was associated to
clinical outcome. Patients with <, 2 N + showed a higher
probability of RFS (43% vs 13%, P = 0.0004) and survival
(66% vs 46%, P = 0.04) than patients with >2 N + (Figure
3a,b). Moreover, the probability of RFS at 3 years was
significantly lower for patients with extracapsular diffusion of
disease (27%) than for patients with intracapsular disease
(44%; P = 0.03) (Figure 4a). Within the latter group, a
different RFS was observed for patients with partial or mas-
sive nodal involvement. No statistically significant difference
was observed among the corresponding survival curves.
(Figure 4b). Age and sex of patients did not affect RFS or
survival.
Multiple regression analysis was carried out to evaluate the
joint effect of prognostic factors on RFS and survival. Age
and sex were excluded from the evaluation because, by single
factor analysis, they were clearly not associated with RFS
and survival. The 3H-TdR LI was added to the regression
models including the two pathologic variables, i.e. number of
positive nodes and type of nodal invasion (Table II). With
regard to RFS, the hazard ratio was maximum for number
of positive nodes. 3H-TdR LI, as in the univariate analysis,
retained its statistical significance and provided a prognostic
contribution to the other variables considered in the model
(likelihood ratio test: x = 5.74, 1 d.f., P = 0.017). Type of
nodal invasion did not reach the significance level. 3H-TdR
LI became the most important prognostic indicator of sur-
vival compared to the pathologic variables (likelihood ratio
test: X = 7.23, 1 d.f., P = 0.007).
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Figure 3 Clinical outcome as a function of number of positive
nodes in a series of 145 patients with stage II melanoma of the
skin. ---, < 2 N +; -, > 2 N + . a, relapse-free survival; b,
survival.
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Figure 4 Clinical outcome as a function of type of nodal
invasion in a series of 145 patients with stage II melanoma of the
skin. ---, intracapsular invasion; -, extracapsular invasion. a,
relapse-free survival; b, survival.
Discussion
Tumour thickness is the most important factor in predicting
the risk of nodal metastases in stage I melanoma patients,
but it no longer has any prognostic value once nodal metas-
tases have developed. At such a time, in stage II patients,
nodal status becomes the most important determinant of
evolution, i.e. the second step of melanoma life is mainly
conditioned by number of involved nodes and type of nodal
metastases (Balch et al., 1981; Rayner et al., 1981; Callery et
al., 1982; Cascinelli et al., 1984). This finding has been
confirmed in the present series of patients: 3-year RFS and
survival were significantly lower for patients with more than
two positive nodes and massive invasion, regardless of
diffusion beyond the capsule.
As observed for other human tumours (Meyer et al., 1983;
Tubiana et al., 1984; Silvestrini et al., 1986, 1989a,b; Chauvel
et al., 1988), cell kinetics varies widely from patient to
patient, and there is no evident relationship between 3H-TdR
LI of metastatic lesions and clinico-pathologic features con-
sidered to be prognostic factors in stage II melanoma
patients.
The present study confirms the previous finding on the value
of cell kinetics as a prognostic factor in stage II melanoma
patients subjected to nodal dissection (Hansson et al., 1982;
Table II Final model of Cox's regression analysis relative to relapse-free and overall
survival
RFS Survival
Hazard 95% confidence Hazard 95% confidence
Variable ratio limits ratio limits
No. ofpositive nodes
>2 vs K2 2.0 1.3-3.1 1.9 1.0-3.6
Type ofnodal metastasis
Extra vs intracapsular 1.3 0.8-2.1 1.1 0.6-2.2
3H-TdR LI
High vs low 1.7 1.1-2.6 2.3 1.3-4.1
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Costa et al., 1987), even after making allowance for all the
other known prognostic factors. In fact, multiple regression
analysis showed that 3H-TdR LI retained its importance as
an indicator of RFS and became the most important
indicator of survival even in the presence of number of
involved nodes and type of nodal metastases, at least for the
first 3 years after surgery. Our findings, which reproduce
those reported for other tumour types (Meyer et al., 1983;
Tubiana et al., 1984; Silvestrini et al., 1986, 1989a,b; Chauvel
et al., 1988), indicate that, even for stage II melanoma
patients, cell kinetics should improve the assessment of prog-
nosis.
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